Baby's hand holding its mother's finger


Latest News


Publication Demonstrates Ability of Sera Prognostics’ PreTRM® Biomarker Test as a Predictor of Adverse Pregnancy Outcomes

May 20, 2020 – Sera Prognostics, Inc., The Pregnancy Company® announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal Medicine.

Sera Prognostics Appoints Jay M. Moyes as Chief Financial Officer

April 2, 2020 – Sera announced the appointment of Jay M. Moyes as Chief Financial Officer.

Sera Prognostics to Present at the 40th Annual Cowen Health Care Conference

Feb 24, 2020 — Sera will be presenting at the upcoming Cowen 2020 Health Care Conference at the Boston Marriott Copley Place in Boston on Tuesday, March 3rd, at 11:30 a.m. ET.

Data Confirming Performance of Sera Prognostic’s PreTRM® Test Predictor in an Independent Large Cohort and Testing Enhancements to be Presented at the Society for Maternal-Fetal Medicine’s 40th Annual Pregnancy Meeting

Jan 28, 2020 — Sera announced two podium presentations describing the performance of the company’s technologies for predicting the individual risk of prematurity for women when prospectively tested in mid pregnancy.

Sera Prognostics Announces Completion Of Important Prevent PTB Clinical Intervention Study Using The Pretrm® Test

Jan 9, 2020 – Sera announced the completion of the Prevent PTB clinical study conducted by Intermountain Healthcare. This study is the first of its kind to measure the impact on maternal and neonatal health and healthcare costs when standard medical interventions are used to proactively treat mothers screened at high risk for prematurity by the PreTRM® Test.

Sera Prognostics to Present at the 38th Annual JP Morgan Healthcare Conference

Jan 6, 2020 — Sera Prognostics will be presenting at the upcoming JP Morgan 2020 Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 15th, at 3:30 p.m. PT.

New Scientific Publication Shows Sera Prognostics Is Leader In Assessing Preterm Birth Risk

Nov 18, 2019 – Sera announced that a key scientific publication, “Effects of Selective Exclusion of Patients on Preterm Birth Test Performance,” authenticates Sera as the leading authority in using biomarkers to assess preterm birth risk.

Sera Prognostics Raises $36 Million Series D Financing Led By Blue Ox Healthcare Partners

Nov. 13, 2019 – Sera announced it has raised $36 million in Series D financing led by Blue Ox Healthcare Partners, an investment firm providing growth capital to healthcare companies targeting individuality and value-based care.

Sera Prognostics to Present at the 31st Annual Piper Jaffray Healthcare Conference

Nov. 1, 2019 — Sera Prognostics will be presenting at the upcoming Piper Jaffray Healthcare Conference at the Lotte New York Palace in New York City on Thursday, December 5th at 12:30 p.m. ET.

Sera Prognostics to Present at the 13th Annual Canaccord Genuity Medical Technologies & Diagnostics Forum

Oct. 21, 2019 — Sera Prognostics announced that Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will be presenting at the upcoming Canaccord Genuity Medical Technologies and Diagnostics Forum at the Westin Grand Central Hotel in New York City on Thursday, November 21st, at 3:00 p.m. ET

Stay in Touch